At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 404 enrolled
Drug / intervention
T2345 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients
In Brief
A Phase 3 clinical trial evaluating T2345 and Prostaglandin for Glaucoma. Completed, enrolled 404 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedJul 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedJul 2, 2010
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16 years ago
Interventions
T2345drug
One drop of T2345
Prostaglandindrug
One drop